HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics

HICC：COVID19 的体液免疫相关性：定义疫苗和治疗临床试验的保护性反应和关键读数

• 批准号: MC_PC_20016
• 负责人: Wilhelm Schwaeble
• 金额: $ 101.13万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_20016
• 关键词: HICC; Humoral; Immune; Correlates; COVID19

SARS-CoV-2 is an emerging virus with very high infectivity and risk of death in those with severe respiratory symptoms. To maximise our success in protecting people against this disease, we urgently need to understand and develop highly accurate tests to identify when a person has developed a protective immune response versus a COVID-19 disease response. We do not understand the antibody response differences between individuals who have mild SARS-CoV-2 infection and high risk patients that progress to life threatening disease. Understanding specific differences will help us develop tests to diagnose the likelihood of severe disease, and vaccines to prevent them. We will use cutting edge, high throughput technologies to identify in detail the functional role of SARS-CoV-2 antibodies in immune protection, their association with disease severity and the duration of immunity after infection. Importantly, we will turn this information into tests which will be used to:1. Identify when NHS-staff have evidence of protective antibody responses to SARS-CoV-2. This is urgently needed to manage NHS staff returns, guide public health and government policy.2. Provide clinical tests to assist the development and evaluation of safe vaccines and therapies for the treatment of the sickest patients.

SARS-CoV-2是一种新出现的病毒，具有非常高的传染性，在有严重呼吸道症状的人中具有死亡风险。为了最大限度地成功保护人们免受这种疾病的侵害，我们迫切需要了解和开发高度准确的测试，以确定一个人何时产生了保护性免疫反应，而不是COVID-19疾病反应。我们不了解轻度SARS-CoV-2感染者和进展为危及生命的疾病的高危患者之间的抗体反应差异。了解具体的差异将有助于我们开发诊断严重疾病可能性的测试和预防它们的疫苗。我们将使用尖端的高通量技术来详细确定SARS-CoV-2抗体在免疫保护中的功能作用，它们与疾病严重程度的关系以及感染后免疫力的持续时间。重要的是，我们将把这些信息转化为测试，用于：1。确定NHS工作人员何时有SARS-CoV-2保护性抗体反应的证据。这是迫切需要管理NHS工作人员返回，指导公共卫生和政府政策。提供临床试验，以协助开发和评估用于治疗最严重患者的安全疫苗和疗法。

项目成果

Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.

• DOI: 10.3389/fimmu.2021.748291
• 发表时间: 2021
• 期刊: Frontiers in immunology
• 影响因子: 7.3
• 作者: Castillo-Olivares J;Wells DA;Ferrari M;Chan ACY;Smith P;Nadesalingam A;Paloniemi M;Carnell GW;Ohlendorf L;Cantoni D;Mayora-Neto M;Palmer P;Tonks P;Temperton NJ;Peterhoff D;Neckermann P;Wagner R;Doffinger R;Kempster S;Otter AD;Semper A;Brooks T;Albecka A;James LC;Page M;Schwaeble W;Baxendale H;Heeney JL
• 通讯作者: Heeney JL

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.

• DOI: 10.1016/j.ebiom.2022.104402
• 发表时间: 2023-01
• 期刊: EBIOMEDICINE
• 影响因子: 11.1
• 作者: Liew, Felicity;Talwar, Shubha;Cross, Andy;Willett, Brian J.;Scott, Sam;Logan, Nicola;Siggins, Matthew K.;Swieboda, Dawid;Sidhu, Jasmin K.;Efstathiou, Claudia;Moore, Shona C.;Davis, Chris;Mohamed, Noura;Nunag, Jose;King, Clara;Thompson, A. A. Roger;Rowland-Jones, Sarah L.;Docherty, Annemarie B.;Chalmers, James D.;Ho, Ling-Pei;Horsley, Alexander;Raman, Betty;Poinasamy, Krisnah;Marks, Michael;Kon, Onn Min;Howard, Luke;Wootton, Daniel G.;Dunachie, Susanna;Quint, Jennifer K.;Evans, Rachael A.;V. Wain, Louise;Fontanella, Sara;Silva, Thushan I. de;Ho, Antonia;Harrison, Ewen;Baillie, J. Kenneth;Semple, Malcolm G.;Brightling, Christopher;Thwaites, Ryan S.;Turtle, Lance;Openshaw, Peter J. M.
• 通讯作者: Openshaw, Peter J. M.

Secondary Complement Deficiency Impairs Anti-Microbial Immunity to Klebsiella pneumoniae and Staphylococcus aureus During Severe Acute COVID-19.

• DOI: 10.3389/fimmu.2022.841759
• 发表时间: 2022
• 期刊: Frontiers in immunology
• 影响因子: 7.3

Breadth of neutralizing antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection; studies in UK healthcare workers and immunodeficient patients

通过在先前感染后接种疫苗，可以增强对所关注的 SARS-CoV-2 变体的中和抗体反应的广度；

• DOI: 10.6084/m9.figshare.14740371
• 发表时间: 2021
• 作者: Nadesalingam A

Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes

• DOI: 10.21769/bioprotoc.4236
• 发表时间: 2021-11-05
• 期刊: BIO-PROTOCOL
• 影响因子: 0.8
• 作者: Di Genova, Cecilia;Sampson, Alex;Temperton, Nigel
• 通讯作者: Temperton, Nigel